{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T09:29:53Z","timestamp":1792056593231,"version":"4.4.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,8,5]],"date-time":"2027-08-05T00:00:00Z","timestamp":1817424000000},"content-version":"am","delay-in-days":369,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["R01NS110596"],"award-info":[{"award-number":["R01NS110596"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["320030_207965"],"award-info":[{"award-number":["320030_207965"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Schweizerischer Nationalfonds zur F\u00f6rderung der Wissenschaftlichen Forschung","doi-asserted-by":"publisher","award":["CRSII--222794"],"award-info":[{"award-number":["CRSII--222794"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100020026","name":"Citrin Foundation","doi-asserted-by":"publisher","award":["RG24003"],"award-info":[{"award-number":["RG24003"]}],"id":[{"id":"10.13039\/501100020026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ymthe.2026.04.045","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T16:10:41Z","timestamp":1777306241000},"page":"4449-4465","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["A hybrid piggyBac AAV-transposon and LNP-transposase for treating arginase deficiency: A 100-fold dose reduction compared to AAV alone"],"prefix":"10.1016","volume":"34","author":[{"given":"Rachel","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taryn","family":"Diep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiran","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuti","family":"Bakshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace F.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mimi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Schwerk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"H\u00e4berle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Schulze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilona","family":"Tkachyova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Poms","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie","family":"Jacques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Rychak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Jun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7876-6776","authenticated-orcid":false,"given":"Gerald S.","family":"Lipshutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2026.04.045_bib1","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13023-022-02226-8","article-title":"Arginase 1 Deficiency: using genetic databases as a tool to establish global prevalence","volume":"17","author":"Catsburg","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymthe.2026.04.045_bib2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ymgme.2011.06.025","article-title":"Arginase I deficiency: severe infantile presentation with hyperammonemia: more common than reported?","volume":"104","author":"Jain-Ghai","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2026.04.045_bib3","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1067\/mpd.2003.97","article-title":"Arginase deficiency with lethal neonatal expression: evidence for the glutamine hypothesis of cerebral edema","volume":"142","author":"Picker","year":"2003","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymthe.2026.04.045_bib4","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/BF00210403","article-title":"Molecular basis of phenotypic variation in patients with argininemia","volume":"96","author":"Uchino","year":"1995","journal-title":"Hum. Genet."},{"key":"10.1016\/j.ymthe.2026.04.045_bib5","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.pediatrneurol.2012.03.016","article-title":"Clinical features and neurologic progression of hyperargininemia","volume":"46","author":"Carvalho","year":"2012","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/j.ymthe.2026.04.045_bib6","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.ymgme.2010.01.012","article-title":"Guanidino compound levels in blood, cerebrospinal fluid, and post-mortem brain material of patients with argininemia","volume":"100","author":"Deignan","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2026.04.045_bib7","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/gt.2012.99","article-title":"AAV-based gene therapy prevents neuropathology and results in normal cognitive development in the hyperargininemic mouse","volume":"20","author":"Lee","year":"2013","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2026.04.045_bib8","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/jnc.15774","article-title":"Guanidinoacetate (GAA) is a potent GABA(A) receptor GABA mimetic: Implications for neurological disease pathology","volume":"165","author":"Meera","year":"2023","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ymthe.2026.04.045_bib9","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/jimd.12343","article-title":"Clinical effect and safety profile of pegzilarginase in patients with arginase 1 deficiency","volume":"44","author":"Diaz","year":"2021","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymthe.2026.04.045_bib10","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1038\/mt.2012.129","article-title":"Long-term survival of the juvenile lethal arginase-deficient mouse with AAV gene therapy","volume":"20","author":"Lee","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.04.045_bib11","doi-asserted-by":"crossref","first-page":"7966","DOI":"10.1073\/pnas.93.15.7966","article-title":"The recombination signals for adeno-associated virus site-specific integration","volume":"93","author":"Linden","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2026.04.045_bib12","doi-asserted-by":"crossref","first-page":"7874","DOI":"10.1128\/JVI.78.15.7874-7882.2004","article-title":"Adeno-associated virus site-specific integration and AAVS1 disruption","volume":"78","author":"Hamilton","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.ymthe.2026.04.045_bib13","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1146\/annurev.genet.37.110801.143717","article-title":"Integration of adeno-associated virus (AAV) and recombinant AAV vectors","volume":"38","author":"McCarty","year":"2004","journal-title":"Annu. Rev. Genet."},{"key":"10.1016\/j.ymthe.2026.04.045_bib14","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1016\/j.ymthe.2021.08.031","article-title":"AAV integration in human hepatocytes","volume":"29","author":"Dalwadi","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.04.045_bib15","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1016\/j.ymthe.2022.06.004","article-title":"Evaluating the state of the science for adeno-associated virus integration: An integrated perspective","volume":"30","author":"Sabatino","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.04.045_bib16","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1182\/bloodadvances.2021006419","article-title":"Fatal thrombotic microangiopathy case following adeno-associated viral SMN gene therapy","volume":"6","author":"Guillou","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2026.04.045_bib17","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1016\/j.ymthe.2023.10.015","article-title":"Lethal immunotoxicity in high-dose systemic AAV therapy","volume":"31","author":"Duan","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.04.045_bib18","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1056\/NEJMoa2307798","article-title":"Death after High-Dose rAAV9 Gene Therapy in a Patient with Duchenne's Muscular Dystrophy","volume":"389","author":"Lek","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymthe.2026.04.045_bib19","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1089\/hum.2024.156","article-title":"Thrombotic Microangiopathy Associated with Systemic Adeno-Associated Virus Gene Transfer: Review of Reported Cases","volume":"36","author":"Laforet","year":"2025","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2026.04.045_bib20","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.ymthe.2024.02.002","article-title":"High-dose systemic adeno-associated virus vector administration causes liver and sinusoidal endothelial cell injury","volume":"32","author":"Hordeaux","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.04.045_bib21","doi-asserted-by":"crossref","DOI":"10.1172\/JCI173510","article-title":"Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies","volume":"134","author":"Salabarria","year":"2024","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2026.04.045_bib22","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1177\/10430342251359668","article-title":"The Responsible Development of Adeno-Associated Virus Gene Therapies","volume":"36","author":"Wilson","year":"2025","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2026.04.045_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1001263","article-title":"rAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis","volume":"13","author":"Shen","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.04.045_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.975803","article-title":"Immunogenicity and toxicity of AAV gene therapy","volume":"13","author":"Ertl","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2026.04.045_bib25","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.ymgme.2013.06.020","article-title":"Lethal phenotype in conditional late-onset arginase 1 deficiency in the mouse","volume":"110","author":"Kasten","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymthe.2026.04.045_bib26","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1002\/jimd.12068","article-title":"Comprehensive characterization of ureagenesis in the spf(ash) mouse, a model of human ornithine transcarbamylase deficiency, reveals age-dependency of ammonia detoxification","volume":"42","author":"Allegri","year":"2019","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymthe.2026.04.045_bib27","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1038\/s41436-019-0442-0","article-title":"Untargeted metabolomic profiling reveals multiple pathway perturbations and new clinical biomarkers in urea cycle disorders","volume":"21","author":"Burrage","year":"2019","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymthe.2026.04.045_bib28","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s44324-025-00051-8","article-title":"Characterization and treatment monitoring of ureagenesis disorders using stable isotopes","volume":"3","author":"Allegri","year":"2025","journal-title":"NPJ Metab. Health Dis."},{"key":"10.1016\/j.ymthe.2026.04.045_bib29","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1080\/14712598.2022.2060737","article-title":"Addressing high dose AAV toxicity - 'one and done' or 'slower and lower'?","volume":"22","author":"Kishimoto","year":"2022","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.ymthe.2026.04.045_bib30","unstructured":"Food and Drug Adminsitration (FDA) Cellular Tissue, and Gene Therapies Advisory Committee (CTGTAC) meeting #70 Brief Document. https:\/\/web.archive.org\/web\/20240123121711\/https:\/\/www.fda.gov\/advisory-committees\/advisory-committee-calendar\/cellular-tissue-and-gene-therapies-advisory-committee-september-2-3-2021-meeting-announcement#event-materials."},{"key":"10.1016\/j.ymthe.2026.04.045_bib31","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.omtm.2017.11.007","article-title":"Emerging Issues in AAV-Mediated In Vivo Gene Therapy","volume":"8","author":"Colella","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2026.04.045_bib32","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1089\/hum.2020.29117.trf","article-title":"Revisiting the \u201cNew\u201d Inflammatory Toxicities of Adeno-Associated Virus Vectors","volume":"31","author":"Flotte","year":"2020","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2026.04.045_bib34","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.r1548","article-title":"Duchenne gene therapy halted after three deaths and company u turn","volume":"390","author":"Taylor","year":"2025","journal-title":"BMJ"},{"key":"10.1016\/j.ymthe.2026.04.045_bib35","author":"Behring"},{"key":"10.1016\/j.ymthe.2026.04.045_bib36","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jhep.2020.11.001","article-title":"Hepatotoxicity following administration of onasemnogene abeparvovec (AVXS-101) for the treatment of spinal muscular atrophy","volume":"74","author":"Chand","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ymthe.2026.04.045_bib37","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2020-0729","article-title":"Gene Therapy for Spinal Muscular Atrophy: Safety and Early Outcomes","volume":"146","author":"Waldrop","year":"2020","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymthe.2026.04.045_bib38","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/j.ekir.2024.04.024","article-title":"Thrombotic Microangiopathy as an Emerging Complication of Viral Vector-Based Gene Therapy","volume":"9","author":"Schwotzer","year":"2024","journal-title":"Kidney Int. Rep."},{"key":"10.1016\/j.ymthe.2026.04.045_bib40","doi-asserted-by":"crossref","DOI":"10.1242\/bio.058678","article-title":"Specificity and off-target effects of AAV8-TBG viral vectors for the manipulation of hepatocellular gene expression in mice","volume":"10","author":"Kiourtis","year":"2021","journal-title":"Biol. Open"},{"key":"10.1016\/j.ymthe.2026.04.045_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0013424","article-title":"Gene therapy in a humanized mouse model of familial hypercholesterolemia leads to marked regression of atherosclerosis","volume":"5","author":"Kassim","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2026.04.045_bib42","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/sj.mt.6300355","article-title":"Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose","volume":"16","author":"Wu","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.04.045_bib43","article-title":"A mutation-independent CRISPR-Cas9-mediated gene targeting approach to treat a murine model of ornithine transcarbamylase deficiency","volume":"6","author":"Wang","year":"2020","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ymthe.2026.04.045_bib44","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/hep.27842","article-title":"Modeling correction of severe urea cycle defects in the growing murine liver using a hybrid recombinant adeno-associated virus\/piggyBac transposase gene delivery system","volume":"62","author":"Cunningham","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.ymthe.2026.04.045_bib45","doi-asserted-by":"crossref","DOI":"10.1002\/jgm.3726","article-title":"Stable transduction of the neonatal mouse liver using a hybrid rAAV\/sleeping beauty transposon gene delivery system","volume":"26","author":"Cunningham","year":"2024","journal-title":"J. Gene Med."},{"key":"10.1016\/j.ymthe.2026.04.045_bib46","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.1016\/j.ymthe.2024.06.021","article-title":"Sleeping Beauty mRNA-LNP enables stable rAAV transgene expression in mouse and NHP hepatocytes and improves vector potency","volume":"32","author":"Zakas","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.04.045_bib47","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.omtm.2023.03.003","article-title":"Prolonged activity of the transposase helper may raise safety concerns during DNA transposon-based gene therapy","volume":"29","author":"Imre","year":"2023","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2026.04.045_bib48","doi-asserted-by":"crossref","DOI":"10.3390\/biom13040658","article-title":"Enhanced Biosafety of the Sleeping Beauty Transposon System by Using mRNA as Source of Transposase to Efficiently and Stably Transfect Retinal Pigment Epithelial Cells","volume":"13","author":"Harmening","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.ymthe.2026.04.045_bib49","first-page":"133","article-title":"A durable gene therapy with a robust AAV-LNP delivery system allowing for a reduced AAV dose","volume":"32","author":"Nitzahn","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.04.045_bib50","doi-asserted-by":"crossref","first-page":"13104","DOI":"10.1073\/pnas.0702778104","article-title":"Existence of transient functional double-stranded DNA intermediates during recombinant AAV transduction","volume":"104","author":"Wang","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2026.04.045_bib51","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/BF00120216","article-title":"Excision of the piggyBac transposable element in vitro is a precise event that is enhanced by the expression of its encoded transposase","volume":"98","author":"Elick","year":"1996","journal-title":"Genetica"},{"key":"10.1016\/j.ymthe.2026.04.045_bib52","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/j.1365-2583.1996.tb00048.x","article-title":"Precise excision of TTAA-specific lepidopteran transposons piggyBac (IFP2) and tagalong (TFP3) from the baculovirus genome in cell lines from two species of Lepidoptera","volume":"5","author":"Fraser","year":"1996","journal-title":"Insect Mol. Biol."},{"key":"10.1016\/j.ymthe.2026.04.045_bib53","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/mt.2016.11","article-title":"Genome-wide Profiling Reveals Remarkable Parallels Between Insertion Site Selection Properties of the MLV Retrovirus and the piggyBac Transposon in Primary Human CD4(+) T Cells","volume":"24","author":"Gogol-D\u00f6ring","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2026.04.045_bib54","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1038\/s41419-022-05408-1","article-title":"Mutant p53 in cancer: from molecular mechanism to therapeutic modulation","volume":"13","author":"Chen","year":"2022","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ymthe.2026.04.045_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2025.102470","article-title":"Use of an oversized AAV8 vector for CPS1 deficiency results in long-term survival and ammonia control","volume":"36","author":"Diep","year":"2025","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2026.04.045_bib56","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.omtn.2022.04.012","article-title":"Intermittent lipid nanoparticle mRNA administration prevents cortical dysmyelination associated with arginase deficiency","volume":"28","author":"Khoja","year":"2022","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.ymthe.2026.04.045_bib57","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.052303","article-title":"A hypomorphic model of CPS1 deficiency for investigating the effects of hyperammonemia on the developing nervous system","volume":"18","author":"Bakshi","year":"2025","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.ymthe.2026.04.045_bib58","doi-asserted-by":"crossref","first-page":"7280","DOI":"10.1038\/s41598-025-92022-8","article-title":"[(18)F]FDG-PET and [(18)F]MPPF-PET are brain biomarkers for the creatine transporter Slc6a8 loss of function mutation","volume":"15","author":"Day","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2026.04.045_bib59","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/978-1-0716-2565-1_12","article-title":"Laboratory Diagnosis of Cerebral Creatine Deficiency Syndromes by Determining Creatine and Guanidinoacetate in Plasma and Urine","volume":"2546","author":"Liu","year":"2022","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ymthe.2026.04.045_bib60","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1203\/00006450-199704000-00012","article-title":"Adenovirus-mediated in vivo gene transfer rapidly protects ornithine transcarbamylase-deficient mice from an ammonium challenge","volume":"41","author":"Ye","year":"1997","journal-title":"Pediatr. Res."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626003102?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001626003102?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T04:47:11Z","timestamp":1786078031000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001626003102"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":58,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1525001626003102"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.04.045","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A hybrid piggyBac AAV-transposon and LNP-transposase for treating arginase deficiency: A 100-fold dose reduction compared to AAV alone","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2026.04.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}